-- Data supporting selection of ROR1 for CB-020 and armoring strategies for Caribou’s CAR-NK cell platform to be presented at AACR-JCA Conference today -- -- Caribou is using its chRDNA next-gen ...
The latest price target for Century Therapeutics (NASDAQ:IPSC) was reported by Leerink Partners on November 17, 2025. The analyst firm set a price target for $2.00 expecting IPSC to rise to within 12 ...
Investing.com - Leerink Partners has lowered its price target on Fate Therapeutics (NASDAQ:FATE) to $7.00 from $12.00 while maintaining an Outperform rating on the stock. The new target still ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback